These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

539 related articles for article (PubMed ID: 24387781)

  • 1. Selecting oral bioavailability enhancing formulations during drug discovery and development.
    Leucuta SE
    Expert Opin Drug Discov; 2014 Feb; 9(2):139-50. PubMed ID: 24387781
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim.
    Sjögren E; Westergren J; Grant I; Hanisch G; Lindfors L; Lennernäs H; Abrahamsson B; Tannergren C
    Eur J Pharm Sci; 2013 Jul; 49(4):679-98. PubMed ID: 23727464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selection of oral bioavailability enhancing formulations during drug discovery.
    Zheng W; Jain A; Papoutsakis D; Dannenfelser RM; Panicucci R; Garad S
    Drug Dev Ind Pharm; 2012 Feb; 38(2):235-47. PubMed ID: 21851310
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro models for the prediction of in vivo performance of oral dosage forms.
    Kostewicz ES; Abrahamsson B; Brewster M; Brouwers J; Butler J; Carlert S; Dickinson PA; Dressman J; Holm R; Klein S; Mann J; McAllister M; Minekus M; Muenster U; Müllertz A; Verwei M; Vertzoni M; Weitschies W; Augustijns P
    Eur J Pharm Sci; 2014 Jun; 57():342-66. PubMed ID: 23988843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrating drug permeability with dissolution profile to develop IVIVC.
    Takano R; Kataoka M; Yamashita S
    Biopharm Drug Dispos; 2012 Oct; 33(7):354-65. PubMed ID: 22581486
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A strategy for preclinical formulation development using GastroPlus as pharmacokinetic simulation tool and a statistical screening design applied to a dog study.
    Kuentz M; Nick S; Parrott N; Röthlisberger D
    Eur J Pharm Sci; 2006 Jan; 27(1):91-9. PubMed ID: 16219449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive approaches to increase absorption of compounds during lead optimisation.
    Valko K; Butler J; Eddershaw P
    Expert Opin Drug Discov; 2013 Oct; 8(10):1225-38. PubMed ID: 23865945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regional intestinal drug permeation: biopharmaceutics and drug development.
    Lennernäs H
    Eur J Pharm Sci; 2014 Jun; 57():333-41. PubMed ID: 23988845
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral biopharmaceutics tools - time for a new initiative - an introduction to the IMI project OrBiTo.
    Lennernäs H; Aarons L; Augustijns P; Beato S; Bolger M; Box K; Brewster M; Butler J; Dressman J; Holm R; Julia Frank K; Kendall R; Langguth P; Sydor J; Lindahl A; McAllister M; Muenster U; Müllertz A; Ojala K; Pepin X; Reppas C; Rostami-Hodjegan A; Verwei M; Weitschies W; Wilson C; Karlsson C; Abrahamsson B
    Eur J Pharm Sci; 2014 Jun; 57():292-9. PubMed ID: 24189462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Increasing the solubility and permeability of pharmacons with pharmaceutical technological methods].
    Aigner Z
    Acta Pharm Hung; 2008; 78(1):3-10. PubMed ID: 18476363
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The influence of lipophilicity in drug discovery and design.
    Arnott JA; Planey SL
    Expert Opin Drug Discov; 2012 Oct; 7(10):863-75. PubMed ID: 22992175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro testing of drug absorption for drug 'developability' assessment: forming an interface between in vitro preclinical data and clinical outcome.
    Sun D; Yu LX; Hussain MA; Wall DA; Smith RL; Amidon GL
    Curr Opin Drug Discov Devel; 2004 Jan; 7(1):75-85. PubMed ID: 14982151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro - in vivo correlation: from theory to applications.
    Emami J
    J Pharm Pharm Sci; 2006; 9(2):169-89. PubMed ID: 16959187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical Bioavailability Strategy for Decisions on Clinical Drug Formulation Development: An In Depth Analysis.
    Van den Bergh A; Van Hemelryck S; Bevernage J; Van Peer A; Brewster M; Mackie C; Mannaert E
    Mol Pharm; 2018 Jul; 15(7):2633-2645. PubMed ID: 29799758
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug dissolution: significance of physicochemical properties and physiological conditions.
    Jambhekar SS; Breen PJ
    Drug Discov Today; 2013 Dec; 18(23-24):1173-84. PubMed ID: 24042023
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biopharmaceutical classification of poorly soluble drugs with respect to "enabling formulations".
    Buckley ST; Frank KJ; Fricker G; Brandl M
    Eur J Pharm Sci; 2013 Sep; 50(1):8-16. PubMed ID: 23583787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent advances in physicochemical and ADMET profiling in drug discovery.
    Wang J; Skolnik S
    Chem Biodivers; 2009 Nov; 6(11):1887-99. PubMed ID: 19937823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biowaiver extension potential and IVIVC for BCS Class II drugs by formulation design: Case study for cyclosporine self-microemulsifying formulation.
    Yang SG
    Arch Pharm Res; 2010 Nov; 33(11):1835-42. PubMed ID: 21116787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Biopharmaceutical classification system--experimental model of the prediction of drug bioavailability].
    Golovenko NIa; Borisiuk IIu
    Biomed Khim; 2008; 54(4):392-407. PubMed ID: 18988456
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of biopharmaceutic classification of drugs in drug discovery and development: current status and future extension.
    Lennernäs H; Abrahamsson B
    J Pharm Pharmacol; 2005 Mar; 57(3):273-85. PubMed ID: 15807982
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.